ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
4.3300
4.3300
Rango anual
3.2700
5.5000
Cambio diario
-0.23%
Variación mensual
+28.49%
Variación en los últimos 6 meses
+9.62%
Cambio anual
+9.62%
Cierres anteriores
4.3400
Abrir
4.3300
Mínimo
4.3300
High
4.3300
Volumen
64
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-1.41
Relación precio/flujo de caja
226.59

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

Noticias